Dominari (DOMH) Competitors $6.33 +0.36 (+6.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DOMH vs. VNDA, CBIO, CDXS, IRWD, SGMO, ACHV, AGEN, FBIO, SABS, and CRISShould you be buying Dominari stock or one of its competitors? The main competitors of Dominari include Vanda Pharmaceuticals (VNDA), Crescent Biopharma (CBIO), Codexis (CDXS), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), and Curis (CRIS). These companies are all part of the "biotechnology" industry. Dominari vs. Its Competitors Vanda Pharmaceuticals Crescent Biopharma Codexis Ironwood Pharmaceuticals Sangamo Therapeutics Achieve Life Sciences Agenus Fortress Biotech SAB Biotherapeutics Curis Vanda Pharmaceuticals (NASDAQ:VNDA) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations. Is VNDA or DOMH more profitable? Vanda Pharmaceuticals has a net margin of -32.90% compared to Dominari's net margin of -36.01%. Vanda Pharmaceuticals' return on equity of -12.89% beat Dominari's return on equity.Company Net Margins Return on Equity Return on Assets Vanda Pharmaceuticals-32.90% -12.89% -10.47% Dominari -36.01%-94.32%-78.21% Which has higher earnings and valuation, VNDA or DOMH? Dominari has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVanda Pharmaceuticals$198.77M1.34-$18.90M-$1.13-4.00Dominari$18.15M5.42-$14.70M-$2.37-2.67 Do institutionals and insiders believe in VNDA or DOMH? 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 10.0% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 33.0% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts prefer VNDA or DOMH? Vanda Pharmaceuticals presently has a consensus price target of $16.50, indicating a potential upside of 265.04%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than Dominari.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Dominari 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, VNDA or DOMH? Vanda Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Does the media refer more to VNDA or DOMH? In the previous week, Vanda Pharmaceuticals and Vanda Pharmaceuticals both had 1 articles in the media. Vanda Pharmaceuticals' average media sentiment score of 1.47 beat Dominari's score of 0.48 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dominari 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVanda Pharmaceuticals beats Dominari on 11 of the 16 factors compared between the two stocks. Get Dominari News Delivered to You Automatically Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DOMH vs. The Competition Export to ExcelMetricDominariMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.80M$2.55B$5.76B$10.29BDividend YieldN/A57.28%5.74%4.60%P/E Ratio-2.6723.4276.8626.96Price / Sales5.42717.16539.94127.44Price / CashN/A169.7137.1760.63Price / Book1.115.4313.836.37Net Income-$14.70M$32.95M$3.29B$271.46M7 Day Performance-9.05%0.84%0.93%2.35%1 Month Performance-3.06%6.04%5.31%7.78%1 Year Performance242.16%-0.89%84.25%32.27% Dominari Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DOMHDominari0.6147 of 5 stars$6.33+6.0%N/A+214.2%$92.80M$18.15M-2.674Short Interest ↑Gap UpVNDAVanda Pharmaceuticals4.085 of 5 stars$4.48+2.2%$16.50+268.7%-11.1%$264.43M$198.77M-3.96290Positive NewsCBIOCrescent Biopharma4.2097 of 5 stars$12.57+2.9%$25.60+103.7%N/A$245.74MN/A-0.3650CDXSCodexis3.2591 of 5 stars$2.48+1.4%$11.00+344.4%-25.6%$222.51M$57.16M-2.97250IRWDIronwood Pharmaceuticals4.2613 of 5 stars$1.31+2.3%$4.94+277.1%-71.4%$212.79M$308.52M-26.19220Positive NewsSGMOSangamo Therapeutics2.9856 of 5 stars$0.52+4.1%$4.50+763.7%-38.5%$156.89M$81.71M-1.79480Positive NewsACHVAchieve Life Sciences2.3176 of 5 stars$3.07+0.8%$14.67+378.5%-33.9%$156.62MN/A-2.1020News CoveragePositive NewsShort Interest ↑AGENAgenus3.9373 of 5 stars$4.51+1.3%$14.50+221.5%-27.0%$143.56M$103.46M-0.63440FBIOFortress Biotech2.6622 of 5 stars$3.43-3.5%$16.50+381.8%+79.2%$101.30M$57.67M-3.24170High Trading VolumeSABSSAB Biotherapeutics3.7907 of 5 stars$2.12+1.0%$10.67+403.1%-6.9%$22.07M$1.32M-0.53140News CoverageAnalyst ForecastCRISCuris2.7572 of 5 stars$1.70-0.1%$17.00+900.6%-72.9%$21.13M$10.91M-0.3560Positive NewsGap Up Related Companies and Tools Related Companies Vanda Pharmaceuticals Competitors Crescent Biopharma Competitors Codexis Competitors Ironwood Pharmaceuticals Competitors Sangamo Therapeutics Competitors Achieve Life Sciences Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Curis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DOMH) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe dollar is failing – here’s your escapeSilver’s 100X Run Is Coming? All gold bull markets follow the same pattern. First, gold moves up. Then majo...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dominari Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dominari With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
